introduction Soft tissue sarcomas (STS) are rare heterogeneous mesenchymal neoplasms, accounting for <1% of adult malignancies, with a median survival of ∼1 year. Several studies have been conducted to find an effective systemic therapy, but currently the number of active drugs is very limited. Results of phase II trials with single or combined regimens, including second-and third-generation agents, showed objective response rates of ∼16%-36% [1] [2] [3] .
Recent advances in the knowledge of molecular characteristics and the prognosis of STS [4, 5] and the development of targeted therapies such as imatinib, sunitinib, Cediranib, and crizotinib may lead to better outcomes by longterm control of the disease [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Sorafenib is one of the most promising multitarget tyrosine-kinase inhibitors, as reported in preclinical and clinical trials [18] [19] [20] [21] [22] . It inhibits tumour cell proliferation and angiogenesis by targeting Raf, vascular endothelial growth factor receptor 2 and 3, and platelet-derived growth factor receptor-β. Therefore in 2006, concomitantly with the study by Maki et al. [23] , we started a phase II trial with sorafenib in metastatic STS refractory to anthracyclinebased therapy, with particular attention to the leiomyosarcoma and angiovascular subtypes.
patients and methods study design
This was a prospective multicentre open-label nonrandomised phase II trial conducted to evaluate the activity of sorafenib in metastatic STS patients. Beginning in November 2006, patients with progressive STS after an adjuvant and/or first-line anthracycline-based regimen were enrolled. Previous therapy with a Raf-kinase, MEK, or farnesyl transferase inhibitor was an exclusion criterion. Eligible patients were at least 18 years old and had histologically confirmed advanced or metastatic STS with at least one measurable unidimensional target lesion (according to the Response Evaluation Criteria in Solid Tumors [RECIST]), an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤2, a life expectancy of 12 weeks or more, and adequate laboratory parameters. Written informed consent was obtained from all patients. Participating centres received ethics committee and institutional review board approval. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. In 2009, during the recruiting phase of the study and because of the positive results published by Maki et al. [23] on leiomyosarcomas and angiovascular sarcomas, the protocol was extended exclusively to these two histologies to obtain an adequate sample size and confirm these data in our population.
Patients received sorafenib 400 mg orally twice daily on a continuous basis until disease progression, unacceptable toxicity, physician's decision, or withdrawal of patient consent. Every 3 weeks, biochemical and clinical evaluation (with blood pressure measurement using a manual sphygmomanometer) was carried out, and safety and drug accountability were monitored. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.
Radiologic tumour assessment was carried out at screening (within 28 days before the start of treatment), every 12 weeks, and at 30 days after treatment end. Tumour responses were assessed according to the RECIST criteria (Version 1.0). Every 12 weeks, patients with stable disease and patients classified as responders continued sorafenib until disease progression, death, toxicity, consent withdrawal, or they were lost to followup. At the discretion of the investigator, patients with progressive disease could continue treatment, in case of clinical evidence of benefit.
According to the criteria by Van Glabbeke et al. [24] , the primary end point was the activity of sorafenib in terms of the progression-free survival (PFS) rate at 6 months, although with an arbitrarily defined higher cut-off (40%) within a biologic therapy setting. To have more clinically relevant results, the cut-off of 40% at 3 months was delayed at 6 months. Secondary end points were overall response rate, overall survival (OS), and toxicity. Patients were considered eligible for analysis if they had received at least 30 days of treatment.
statistical methods
The original study design was planned to enrol STS patients regardless of histotype. During the accrual phase, some studies reported different clinical outcomes in a few histologic STS subtypes, with a greater benefit in patients with angiovascular sarcoma and leiomyosarcoma. On the basis of these considerations, we amended the protocol to obtain an adequate sample size of leiomyosarcomas and angiovascular sarcomas to assess the primary end point separately. A Fleming-Hern single-stage study design for phase II clinical trials was used. Considering an α error of 0.10 and a power of 0.90, it was assumed that a 6-month PFS rate of ≥40%would be of definite clinical value; a PFS rate of ≤25% would indicate the drug should be considered clinically irrelevant. If 10 or more of 30 patients were progression free at 6 months in each histologic subgroup, the hypothesis of inactivity of the treatment would be rejected.
All analyses were carried out assessing all patients who either started treatment with sorafenib (intention to treat [ITT]) or were treated for at least 30 days ( per-protocol [PP]). All data were described by descriptive statistics, as numbers and percentages for categorical data, or as median and range for continuous data.
Overall disease control rate was assessed as the proportion of patients who had a complete response, a partial response (PR), or stable disease (SD) as the best response. PFS was defined as the time between the beginning of therapy and disease progression or death, whichever occurred first, or the last visit date for patients alive and disease free. OS was measured from the date of the beginning of therapy until the date of death or last contact date for patients alive. Survival curves for PFS and OS were computed using a Kaplan-Meier analysis. A P value <0.05 was considered the limit of statistical significance for all secondary evaluations. All statistical analyses were carried out using R Package Version 2.0. 
survival analysis per-protocol analysis
In the 76 analysed patients, we observed a 6-month PFS of 34.5%, with median PFS and OS of 4.2 and 11.9 months, respectively. Thus, the primary end point was not reached in the entire population, regardless of histologic type (Figure 2A and B; Table 4 ). Considering histologic subtypes, leiomyosarcoma patients achieved a 6-month PFS rate of 38.4% (Table 2 ). In particular, the primary end point was achieved in the leiomyosarcoma group with 10 of 30 patients achieving PFS at 6 months. However, in the angiovascular sarcoma patients, the primary end point was not met (5 of 12 patients were progression free at 6 months), mainly due to the incomplete recruitment. There were no statistically significant differences among the histologic subgroups in median PFS and OS (P = 0.145 and P = 0.351). The number of prior therapies did not influence the likelihood of achieving long-term PFS and OS (Table 2) .
intention-to-treat analysis
The results according to ITT analysis on all series of 100 patients were mostly superimposable on those of the PP analysis. The 6-month PFS rate was 27.1%, with median PFS and OS of 2.8 and 10.2 months, respectively. The 6-month PFS in leiomyosarcoma was 35% with a median PFS and OS of 4.9 and 12.5 months, respectively. As shown in Figure 2C and D, a statistically significant benefit was observed in PFS favouring the leiomyosarcoma group (P = 0.033) compared with the other histologies. However, this trend did not reach statistical significance in OS analysis (P = 0.103).
safety
A total of 100 patients were assessable for adverse events. Toxicity data are shown in Table 3 . The most frequently reported side-effects were skin toxicity (42%), fatigue (39%), anorexia (31%), hand-foot skin reaction (28%), and diarrhoea (27%). Most of the reported events were of grade 1 or 2 severity. Grade 3 or higher adverse events included diarrhoea (7%), fatigue (5%), hand-foot syndrome (4%), rash (4%), anorexia (2%), emesis (2%), hypophosphataemia (1%), and 
discussion
STS is a malignancy cluster of >50 histologic subtypes, each one with a distinct underlying biology, natural history, and response to treatment. Overall, STS responds poorly to chemotherapy. Following initial experiences with antiangiogenic agents in STS (sunitinib, imatinib, and bevacizumab), we conducted a phase II study to evaluate the activity of sorafenib. We began by recruiting all STS histologies. Because of the positive results published by Maki et al. on angiovascular sarcoma and leiomyosarcoma, we extended the protocol to these two more responsive histologies [25] .
At the best RECIST response, we observed PRs in leiomyosarcoma (two patients) and angiovascular sarcoma (four patients), but also in fibrosarcoma (two patients) and synovial sarcoma (two patients) [26] with an overall disease control rate (PR plus SD) of 47.4% in both the PP and ITT analyses.
In the leiomyosarcoma group, the primary end point was achieved, confirming the activity of sorafenib in this subset of patients. By contrast, sample size of the angiovascular sarcoma subgroup was too small (12 patients) to define conclusive results. Nonetheless, our results are in line with previous studies [23, 27] showing that sorafenib works in specific histotypes (Table 4) . Maki et al. reported a 6-month PFS rate of 31% in 40 angiovascular sarcoma patients, but the French Sarcoma Group recently demonstrated that sorafenib has a limited antitumour activity in this histotype (6-and 9-month PFS rates of 16% and 3.3%, respectively, in 41 patients), with short-term tumour control.
Considering the relatively high number of patients (24 patients) not assessable according to the protocol for inadequate drug intake, we carried out an ITT analysis to more completely understand the therapeutic implications of sorafenib in clinical practice. The ITT analysis underlined the superior efficacy of sorafenib in leiomyosarcomas relative to the other histologies (P = 0.033). A disappointing result was observed for median PFS and OS in the angiovascular sarcoma group, probably due to either the limited sample size or the delivery of suboptimal treatment (<30 days) in 37% of patients.
Of note, the outcome did not seem to be related to the number of previous chemotherapy lines. As a matter of fact, although almost half of our patients had received at least three chemotherapy lines, there was no significant between-group difference in PFS and OS.
Like other biologic agents, sorafenib demonstrated a good safety profile with few G3-G4 adverse events, but with continuous G1-G2 toxicity in most patients. For instance, n, number; 6-mPFS, 6-month progression-free survival; mPFS, median PFS; mOS, median OS; ORR; overall response rate; DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. many patients reported anorexia, fatigue, diarrhoea, and weight loss, with a significant impact on the quality of everyday life. Nevertheless, no major toxic effects or toxic deaths were observed [28, 29] . 
